Autologous products are created by collecting and concentrating naturally occurring cells from a patient’s own body; these products offer physicians alternative options for patients.
Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient’s own platelets to accelerate the healing of injured tendons, ligaments, muscles and joints. In this way, PRP injections use each individual patient’s own healing system to improve musculoskeletal problems. PRP contains concentrated amounts of the patient’s own growth factors, cytokines, and proteins to promote the healing of damaged tissue.
Platelet-rich Fibrin Matrix (PRM) therapy uses whole blood from the patient to create a 3D autologous fibrin scaffolding (clot). This is a similar alternative to standard PRP, that provides the full compliments of plasma, leukocytes, cytokines, and growth factors that are in an activated fibrin matrix providing a unique structure and sustained release in an exogenous fibrin blood clot scaffold. This exogenous fibrin blood clot can act as a mechanism for short- and long-term delivery of growth factors and a 3D native scaffold for cell adhesion and proliferation.
BMAC (BONE MARROW ASPIRATE CONCENTRATE) is a component of your bone marrow that contains mesenchymal stem cells, growth factors, anti-inflammatory proteins, and similar components found in Platelet Rich Plasma, which have been shown to promote bone and soft tissue healing as well as reduce symptoms of pain related to injuries, tendinitis and arthritis.
Allograft products or tissues (i.e. bone, ligaments, heart valves, fluids, etc.) that are recovered from a human donor for transplantation into another person. Allografts have been successfully used in various medical procedures for more than 150 years. Allograft bone is commonly used in orthopedic, spinal and oral surgeries. Allograft fluids such as exosomes, placental and amniotic tissue/fluid, Wharton’s jelly, cord blood, etc. have been used in the aesthetics and injected for tissue support for tendons, ligaments, and cartilage. Approximately 1.75 million allografts are transplanted each year in the United States. Please note that all Allograft Tissue is regulated by the FDA. Please see attached link to the Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use (https://www.fda.gov/media/109176/download). Many products that are currently being manufactured may not be compliant with the FDA or are currently undergoing an IND (Investigational New Drug) application. Please consult your physician, manufacturer, or the FDA on any product that you consider for use.
An exosome solution contains valuable lipids, messenger-RNA, micro-RNA, signaling cytokines, and proteins. Exosome therapy can be administered through intravenous (IV) therapy or direct injection in the treatment area. Exosomes are powerful elements that can restore cells throughout your body.
What Are Amniotic Fluid Injections? Amniotic injections are comprised of amniotic stem cells (ASCs) that are a mixture of cells from amniotic fluid and tissue. Amniotic fluid is the protective liquid that lubricates the embryo. It is made from maternal blood plasma and is often referred to as “pregnant woman’s water.” They contain cytokines, growth factors, and proteins to promote healing of damaged tissue.
Placental tissue matrix (PTM) injections: Placental tissue matrix injections, also called PTM injections, use placental tissue collected after a healthy birth. Mothers can choose to donate their placenta after giving birth to a child. Placental tissue helps decrease inflammation and promote healing because it contains cellular and structural support.
Wharton’s jelly (substantia gelatinea funiculi umbilicalis) is a gelatinous substance within the umbilical cord, largely made up of mucopolysaccharides (hyaluronic acid and chondroitin sulfate). It acts as a mucous connective tissue containing some fibroblasts and macrophages, and is derived from extra-embryonic mesoderm.
Cord blood (umbilical cord blood) is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders such as cancer.
*Please note that any allograft tissue that is derived from birth tissue may include but not limited to the placenta, umbilical cord, and amniotic fluid/membrane. These tissues helped to nourish your baby while you were pregnant and are normally discarded after birth. With the patient’s permission, following your full-term C-section delivery, the tissue would be harvested and utilized to develop specific allograft products. All allograft products that are donated are respectfully tested, treated, and processed under strict AATB (American Association of Tissue Banks) guidelines to ensure the highest standards of safety.